Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 1999

Li Q, Furman S A, Bradford C R, Chang A E

Abstract excerpt

Generation of tumor-reactive T cells in large numbers ex vivo is a requisite step in the adoptive immunotherapy of patients. We examined the immune responses of T cells derived from tumor vaccine-primed lymph nodes activated with anti-CD3 alone and with an anti-CD3/anti-CD28 combination. Nylon wool-purified CD3+ cells were isolated from vaccine-primed lymph nodes obtained from melanoma, renal cell, and head and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to CD28 Antigens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD3 Complex

Share to CD4-Positive T-Lymphocytes

Share to Cytokines

Share to Histocompatibility Antigens Class II

Share to Lymph Nodes

Share to Lymphocyte Activation

Source

Identifiers

PMID: 10037198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.PMID 10037198Read ↗

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.Semantic proximity Read ↗

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.Semantic proximity Read ↗

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.Semantic proximity Read ↗

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.Semantic proximity Read ↗

The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.Semantic proximity Read ↗

T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine ProductionSemantic proximity Read ↗

Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses <i>in vitro</i>Semantic proximity Read ↗

Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.Semantic proximity Read ↗

Immunological effects of BCG as an adjuvant in autologous tumor vaccines.Semantic proximity Read ↗

Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.Semantic proximity Read ↗

CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.Semantic proximity Read ↗

Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.